Datamonitor Healthcare: data analysis and insight, Pink Shee...
Pharma Intelligence Podcasts
Listen to the Pharma Intelligence podcasts on Spotify, Apple Podcasts, Soundcloud and Alexa
Introduction
BRAND NEW: Our pipeline report now contains an interactive early-phase forecast model and a chapter on early-phase opportunities within asthma – exclusive content you’ll only find at Datamonitor Healthcare.
Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately treated. Biologics in the pipeline for asthma aiming to treat this patient population. Datamonitor Healthcare has provided an in-depth analysis of pipeline products in the US, Japan and five major EU markets, including new clinical data and an evaluation of clinical and commercial drug attributes.
Click here to download your free Table of Contents >>
Click here to download your free Sample Pages >>
How will our asthma pipeline report benefit you?
Key questions answered:
Datamonitor Healthcare: data analysis and insight, Pink Shee...
Listen to the Pharma Intelligence podcasts on Spotify, Apple Podcasts, Soundcloud and Alexa
Topics Coronavirus $name $name Clinical Trials Blog Clinical Trials Drug Pricing
Datamonitor Healthcare: data analysis and insight
The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit.
Datamonitor Healthcare: data analysis and insight, Biomedtra...
Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: